Alaska Air Group, Inc. (NYSE:ALK) reported airlines’ passenger traffic and revenue rose

Alaska Air Group, Inc. (NYSE:ALK) said its airlines’ passenger traffic and revenue rose in December, helped by growth at its regional carriers and its new Virgin America affiliate. SeaTac-based Alaska (NYSE: ALK) also revealed its on-time flight record, as measured by the Department of Transportation, dropped by nearly 10 percent last month.

Alaska Air Group, Inc. (NYSE:ALK) traded 2.13 Million shares and was closed at $92.00 per share. The current share price indicates that stock is 0.12% away from its one year high and is moving 70.12% ahead of its one year low. Stock monthly performance is recorded as 3.90% while its performance in last 5 sessions is 4.55%.

Analyst’s Analysis on Alaska Air Group, Inc. (NYSE:ALK)

At the movement stock is under coverage by number of analysts. 4 given Buy rating to the stock whereas no analyst given UNDERPERFORM rating to stock and 5 analysts given HOLD rating. The consensus recommendation by Thomson Reuters analysts is Outperform and their mean rating for the stock is 2.08 on scale of 1-5. Analysts mean target price for Alaska Air Group, Inc. (NYSE:ALK) is $98.12 while their mean recommendation is 2.20 (1=Buy, 5=sell).

Apricus Biosciences, Inc. (NASDAQ:APRI) shares moved to $1.57 after starting the day at $1.31 on Tuesday. Weekly volatility of APRI is 9.75% and monthly volatility is 13.54%. Stock performance in last five sessions is recorded as 14.60% while year to date (YTD) performance is 20.77%. APRI Gross Margin is 52.00% and its return on assets is -115.50%. Stock 3 months performance is recorded as -55.14%.

Analyst Rating on Apricus Biosciences, Inc. (NASDAQ:APRI)

Number of analysts are covering this stock and currently stock has got OUTPERFORM rating from 2 analysts of Thomson Reuters, 1 analyst given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for APRI is $4.18 while analysts mean recommendation is 2.30.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) said that, it has received approval to sell its influenza treatment in Canada. It’s now available in five countries.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) traded 1.09 Million shares and was closed at $6.19 per share. The current share price indicate that stock is -29.90% away from its one year high and is moving 279.75% ahead of its one year low. Stock monthly performance is recorded as 9.75% while its performance in last 5 sessions is -2.67%.

Analyst’s Analysis on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

At the movement stock is under coverage by number of analysts. At the movement stock is under coverage by number of analysts. 0 given Buy rating to the stock whereas 1 analyst given UNDERPERFORM rating to stock and 3 analysts given HOLD rating. The consensus recommendation by Thomson Reuters analysts is Hold and their mean rating for the stock is 2.62 on scale of 1-5. Analysts mean target price for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is $7.08 while their mean recommendation is 2.60 (1=Buy, 5=sell).

Norfolk Southern Corporation (NYSE:NSC) shares moved to $109.26 after starting the day at $109.23 on Tuesday. Weekly volatility of NSC is 2.34% and monthly volatility is 1.85%. Stock performance in last five sessions is recorded as 2.12% while year to date (YTD) performance is 1.10%. NSC Gross Margin is 42.70% and its return on assets is 4.70%. Firm quarterly performance is 14.75%.

Analyst Recommendation on Norfolk Southern Corporation (NYSE:NSC)

Number of analysts are covering this stock and currently stock has got OUTPERFORM rating from 5 analysts of Thomson Reuters, 17 analysts given HOLD rating to the stock and 1 given UNDERPERFORM rating to Norfolk Southern Corporation (NYSE:NSC) stock. Analyst’s mean target price for NSC is $105.46 while analysts mean recommendation is 2.50.

Leave a Reply

Your email address will not be published. Required fields are marked *